58 related articles for article (PubMed ID: 11878578)
1. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
[TBL] [Abstract][Full Text] [Related]
2. Promising therapeutic targets in neuroblastoma.
Matthay KK; George RE; Yu AL
Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
[TBL] [Abstract][Full Text] [Related]
3. Comparison between whole-body magnetic resonance imaging and whole-body metaiodobenzylguanidine scintigraphy in the evaluation of primary tumor and metastases in neuroblastoma.
Rodrigues MMC; Lederman HM; Grossman I; Castiglioni MLV; Marchetti R; Grass DC; Luisi FAV; Caran EMM
Pediatr Blood Cancer; 2024 Mar; 71(3):e30820. PubMed ID: 38153317
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
Uttenreuther-Fischer MM; Huang CS; Yu AL
Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
[TBL] [Abstract][Full Text] [Related]
5. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.
Xia J; Zhang H; Hu Q; Liu SY; Zhang LQ; Zhang A; Zhang XL; Wang YQ; Liu AG
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):649-660. PubMed ID: 29058276
[TBL] [Abstract][Full Text] [Related]
6. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
[TBL] [Abstract][Full Text] [Related]
7. Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.
Feng L; Li S; Wang C; Yang J
Semin Nucl Med; 2023 Jul; 53(4):517-529. PubMed ID: 36682980
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.
Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL
Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.
Handgretinger R; Baader P; Dopfer R; Klingebiel T; Reuland P; Treuner J; Reisfeld RA; Niethammer D
Cancer Immunol Immunother; 1992; 35(3):199-204. PubMed ID: 1638557
[TBL] [Abstract][Full Text] [Related]
10. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2.
Pancook JD; Becker JC; Gillies SD; Reisfeld RA
Cancer Immunol Immunother; 1996 Feb; 42(2):88-92. PubMed ID: 8620525
[TBL] [Abstract][Full Text] [Related]
11. Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology.
Méhes G; Luegmayr A; Kornmüller R; Ambros IM; Ladenstein R; Gadner H; Ambros PF
Am J Pathol; 2003 Aug; 163(2):393-9. PubMed ID: 12875961
[TBL] [Abstract][Full Text] [Related]
12. Localization of human sarcoma with radiolabeled monoclonal antibody--a follow-up report.
Greager JA; Chao TC; Brown JM; Pavel DG; Blend MJ; Das Gupta TK
Cancer Immunol Immunother; 1991; 33(5):341-5. PubMed ID: 1868492
[TBL] [Abstract][Full Text] [Related]
13. Late Relapse in Neuroblastoma: Case Report and Review of the Literature.
Kebudi R; Koc B; Sozmen BO
Curr Pediatr Rev; 2023 Oct; ():. PubMed ID: 37929737
[TBL] [Abstract][Full Text] [Related]
14. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.
Parikh NS; Howard SC; Chantada G; Israels T; Khattab M; Alcasabas P; Lam CG; Faulkner L; Park JR; London WB; Matthay KK;
Pediatr Blood Cancer; 2015 Aug; 62(8):1305-16. PubMed ID: 25810263
[TBL] [Abstract][Full Text] [Related]
15. Biology of GD2 ganglioside: implications for cancer immunotherapy.
Machy P; Mortier E; Birklé S
Front Pharmacol; 2023; 14():1249929. PubMed ID: 37670947
[TBL] [Abstract][Full Text] [Related]
16. Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.
Schmitt J; Schwenck J; Maurer A; Przybille M; Sonanini D; Reischl G; Wehrmüller JE; Quintanilla-Martinez L; Gillies SD; Krueger MA; Schaefer JF; la Fougère C; Handgretinger R; Pichler BJ
Theranostics; 2022; 12(13):5615-5630. PubMed ID: 35966592
[No Abstract] [Full Text] [Related]
17. [Radiological imaging of neuroblastoma].
Körber F; Schäfer JF
Radiologe; 2021 Jul; 61(7):639-648. PubMed ID: 34156482
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibody Therapies for High Risk Neuroblastoma.
Furman WL
Biologics; 2021; 15():205-219. PubMed ID: 34135571
[TBL] [Abstract][Full Text] [Related]
19.
Zhang Y; Kupferschlaeger J; Lang P; Reischl G; Handgretinger RJ; Fougère C; Dittmann H
J Nucl Med; 2022 Feb; 63(2):205-211. PubMed ID: 34049985
[TBL] [Abstract][Full Text] [Related]
20. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging.
Houvast RD; Vankemmelbeke M; Durrant LG; Wuhrer M; Baart VM; Kuppen PJK; de Geus-Oei LF; Vahrmeijer AL; Sier CFM
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
